Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. more
Time Frame | BEAM | Sector | S&P500 |
---|---|---|---|
1-Week Return | 3.81% | -2.12% | -3% |
1-Month Return | 18.4% | -3.42% | -0.73% |
3-Month Return | 13.04% | -11.13% | 2.87% |
6-Month Return | 25.85% | -5.74% | 7.17% |
1-Year Return | 4.94% | 3.97% | 25.31% |
3-Year Return | -65.19% | 1.05% | 28.38% |
5-Year Return | 54.64% | 34.37% | 81.89% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 18.00K | 24.00K | 51.84M | 60.92M | 377.71M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.01,"profit":true},{"date":"2021-12-31","value":13.73,"profit":true},{"date":"2022-12-31","value":16.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 5.41M | 103.18M | 16.44M | 22.58M | 437.38M | [{"date":"2019-12-31","value":1.24,"profit":true},{"date":"2020-12-31","value":23.59,"profit":true},{"date":"2021-12-31","value":3.76,"profit":true},{"date":"2022-12-31","value":5.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (5.39M) | (103.16M) | 35.40M | 38.34M | (59.67M) | [{"date":"2019-12-31","value":-14.05,"profit":false},{"date":"2020-12-31","value":-269.03,"profit":false},{"date":"2021-12-31","value":92.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-155.63,"profit":false}] |
Gross Margin | (29938.89%) | (429812.50%) | 68.29% | 62.94% | (15.80%) | [{"date":"2019-12-31","value":-43842.38,"profit":false},{"date":"2020-12-31","value":-629415.55,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":92.17,"profit":true},{"date":"2023-12-31","value":-23.14,"profit":false}] |
Operating Expenses | 75.17M | 132.78M | 444.31M | 399.40M | 554.19M | [{"date":"2019-12-31","value":13.56,"profit":true},{"date":"2020-12-31","value":23.96,"profit":true},{"date":"2021-12-31","value":80.17,"profit":true},{"date":"2022-12-31","value":72.07,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (75.15M) | (132.76M) | (392.46M) | (338.48M) | (176.49M) | [{"date":"2019-12-31","value":-7515400000,"profit":false},{"date":"2020-12-31","value":-13276000000,"profit":false},{"date":"2021-12-31","value":-39246500000,"profit":false},{"date":"2022-12-31","value":-33847900000,"profit":false},{"date":"2023-12-31","value":-17648500000,"profit":false}] |
Total Non-Operating Income/Expense | (873.00K) | (60.26M) | 21.82M | 93.60M | 87.55M | [{"date":"2019-12-31","value":-0.93,"profit":false},{"date":"2020-12-31","value":-64.39,"profit":false},{"date":"2021-12-31","value":23.31,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.54,"profit":true}] |
Pre-Tax Income | (78.33M) | (194.59M) | (370.64M) | (260.18M) | (131.16M) | [{"date":"2019-12-31","value":-7832600000,"profit":false},{"date":"2020-12-31","value":-19459200000,"profit":false},{"date":"2021-12-31","value":-37063800000,"profit":false},{"date":"2022-12-31","value":-26017800000,"profit":false},{"date":"2023-12-31","value":-13116100000,"profit":false}] |
Income Taxes | 116.00K | 61.83M | (29.28M) | 3.41M | 1.37M | [{"date":"2019-12-31","value":0.19,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-47.35,"profit":false},{"date":"2022-12-31","value":5.51,"profit":true},{"date":"2023-12-31","value":2.21,"profit":true}] |
Income After Taxes | (78.44M) | (256.42M) | (341.36M) | (263.59M) | (132.53M) | [{"date":"2019-12-31","value":-7844200000,"profit":false},{"date":"2020-12-31","value":-25642400000,"profit":false},{"date":"2021-12-31","value":-34136000000,"profit":false},{"date":"2022-12-31","value":-26358800000,"profit":false},{"date":"2023-12-31","value":-13252700000,"profit":false}] |
Income From Continuous Operations | (78.33M) | (194.59M) | (370.64M) | (289.09M) | (313.67M) | [{"date":"2019-12-31","value":-7832600000,"profit":false},{"date":"2020-12-31","value":-19459200000,"profit":false},{"date":"2021-12-31","value":-37063800000,"profit":false},{"date":"2022-12-31","value":-28908800000,"profit":false},{"date":"2023-12-31","value":-31367300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (78.44M) | (256.42M) | (341.36M) | (263.59M) | (132.53M) | [{"date":"2019-12-31","value":-7844200000,"profit":false},{"date":"2020-12-31","value":-25642400000,"profit":false},{"date":"2021-12-31","value":-34136000000,"profit":false},{"date":"2022-12-31","value":-26358800000,"profit":false},{"date":"2023-12-31","value":-13252699900,"profit":false}] |
EPS (Diluted) | (6.36) | (4.10) | (5.94) | (4.13) | (1.90) | [{"date":"2019-12-31","value":-636,"profit":false},{"date":"2020-12-31","value":-410,"profit":false},{"date":"2021-12-31","value":-594,"profit":false},{"date":"2022-12-31","value":-413,"profit":false},{"date":"2023-12-31","value":-190,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BEAM | |
---|---|
Cash Ratio | 5.57 |
Current Ratio | 5.69 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BEAM | |
---|---|
ROA (LTM) | -9.28% |
ROE (LTM) | -18.29% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BEAM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.32 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.68 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BEAM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 6.36 |
P/B | 2.81 |
Price/FCF | NM |
EV/R | 4.17 |
EV/Ebitda | NM |
Beam Therapeutics Inc (BEAM) share price today is $29.01
Yes, Indians can buy shares of Beam Therapeutics Inc (BEAM) on Vested. To buy Beam Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BEAM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Beam Therapeutics Inc (BEAM) via the Vested app. You can start investing in Beam Therapeutics Inc (BEAM) with a minimum investment of $1.
You can invest in shares of Beam Therapeutics Inc (BEAM) via Vested in three simple steps:
The 52-week high price of Beam Therapeutics Inc (BEAM) is $49.5. The 52-week low price of Beam Therapeutics Inc (BEAM) is $20.84.
The price-to-earnings (P/E) ratio of Beam Therapeutics Inc (BEAM) is
The price-to-book (P/B) ratio of Beam Therapeutics Inc (BEAM) is 2.81
The dividend yield of Beam Therapeutics Inc (BEAM) is 0.00%
The market capitalization of Beam Therapeutics Inc (BEAM) is $2.19B
The stock symbol (or ticker) of Beam Therapeutics Inc is BEAM